Knowledge HQ

This phase 1/2 trial evaluated virus-specific T cells (VSTs) for adenovirus infection post-transplant. VSTs were manufactured using G-Rex 10-M devices for 11-12 days. The therapy was highly effective (81% response rate), and efficacy correlated with Class II HLA restriction.

The authors developed Virus Induced Lymphocytes (VIL) for COVID-19 using artificial APCs (VIPR particles). G-Rex plates were used to facilitate rapid expansion (7 days) of SARS-CoV-2 specific T cells. The resulting VILs showed a polyfunctional cytokine profile and effector memory phenotype.

This study used a KPROR1 lung cancer model to show that immunogenic chemotherapy (Ox/Cy) enhances ROR1 CAR-T cell infiltration. Clinical human ROR1 CAR-T cells were expanded in G-Rex. The combination of Ox/Cy, CAR-T, and anti-PD-L1 improved survival.

The study combines oncolytic adenovirus (CAdTrio) with HER2-CAR T cells to treat pancreatic cancer. NK cells, expanded in G-Rex devices with feeder cells, were also used in experiments. The combination therapy modulated the tumor microenvironment and improved CAR-T infiltration and efficacy.

This paper outlines the CARAMBA clinical trial for SLAMF7 CAR-T cells generated via Sleeping Beauty transposon. The GMP manufacturing process utilizes G-Rex culture for the expansion of CAR-T cells over 12 days. This is the first clinical trial using advanced Sleeping Beauty technology.

The authors investigate MAGE-A3 as a therapeutic target, proposing EPS8L2 as the source of prior TCR-T neurotoxicity. They developed MAGE-A3-directed CARs and TCRs, expanding transduced primary T cells in G-Rex plates. The CARs showed improved selectivity against the off-target peptide.

Knockout of DNMT3A in CAR-T cells prevents exhaustion and enhances antitumor activity. G-Rex-6M culture plates were used for the expansion of gene-edited CAR-T cells. The modified cells retained a stem-like epigenetic program and showed superior tumor control in vivo.

This study evaluates 89Zr-Df-IAB22M2C PET imaging to track CD8+ T cells in a colorectal cancer model treated with a GUCY2C-CD3 bispecific antibody. G-Rex devices were used to expand human T cells prior to adoptive transfer. The tracer effectively monitored dose-dependent T cell infiltration.

RNA-seq revealed that ex vivo expansion alters chemokine receptor expression in NK cells, notably upregulating CCR5. G-Rex were used to expand NK cells with feeder cells. CRISPR-mediated CCR5 disruption reduced liver trafficking and increased NK cell presence in circulation in mice.

The study presents a microfluidic device (VECT) for mRNA delivery into primary T cells, NK cells, and HSPCs. G-Rex plates were used for the culture of NK cells during the expansion phase. The method achieved high transfection efficiency and viability without compromising cell function.

This study repurposes non-transplantable umbilical cord blood units to generate myeloid dendritic cells (DCs) and bivalent-leukemia-specific T cells. G-Rex were used to expand DCs from CD34+ cells, facilitating scalable production. The generated T cells showed specificity against WT1 and PRAME.

The authors generated "Cerberus" T cells (Cb-STs) targeting multiple viruses and Aspergillus fumigatus, with CRISPR/Cas9-mediated glucocorticoid receptor disruption. G-Rex10 devices were used for the culture and expansion of these multi-pathogen specific T cells. Cb-STs maintained function in the presence of dexamethasone.